Xspray Pharma appoints Global Head of Marketing and Sales

Regulatory press release 2022-02-07

Xspray Pharma AB (publ), (Nasdaq Stockholm: XSPRAY) announced today that the company has hired Anna-Karin Ekberg as Global Head of Marketing and Sales. She will take office in mid-March 2022. 
“At the beginning of the year, Xspray Pharma reached a substantial milestone when the FDA accepted to review our first product. This means that we are getting closer to the commercialization phase. Anna-Karin’s solid experience in hematology, in combination with a broad understanding of the international industry – especially in the US – means we can now begin building up the commercial aspect of the organization. I am very much looking forward to welcoming her to the company,” says Per Andersson, CEO of Xspray Pharma.
With lengthy Swedish and international experience in drug marketing and sales, Anna-Karin comes most recently from her position as Global Marketing Director at Oncopeptides AB. She previously had similar strategic and operational roles at companies including Novartis, Schering AG and HRA Pharma. Anna-Karin’s background includes both studies in marketing at IHM Business School and studies in nursing at Uppsala University.
“I am impressed with Xspray Pharma’s achievements so far, and I hope to be able to contribute through my international experiences and many years in relevant areas of disease, as well as knowledge that covers both biotech and drugs,” says Anna-Karin Ekberg. 
Anna-Karin will take office on March 15, 2022 and will become part of Xspray Pharma’s management group.